The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
In the latest industry recall of “sartan”-containing products, Torrent Pharmaceuticals, an Ahmedabad, India-based pharmaceutical company, is expanding its recall for losartan potassium tablets USP and losartan potassium/hydrochlorothiazide tablets,...
Eli Lilly and Company has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor (cefaclor) and Vancocin (vancomcycin), as well as a manufacturing facility in Suzhou, China that produces Ceclor, to...
Novartis has appointed Richard Saynor as Chief Executive Officer (CEO) of Sandoz, the company’s biosimilars and generics business, effective no later than August 1, 2019. He will be a member of the Executive Committee of Novartis and report to Vas...
GlaxoSmithKline (GSK) has announced $100 million of new investment in its manufacturing site in Hamilton, Montana to expand the production capacity of key components of the adjuvant system used in several of its vaccines, including Shingrix, a...
Kite, part of Gilead Sciences, has announced plans for a new facility in Frederick County, Maryland, which will produce cell therapies for treating cancer. The 20-acre site will expand Kite’s ability to manufacture a variety of chimeric antigen...
The Center for Process Innovation (CPI), the process manufacturing arm of the UK government’s network of Catapult centers that are designed to encourage innovation in specific areas, is partnering with GlaxoSmithKline and AstraZeneca to establish a...
Novo Nordisk plans to invest DKK 650 million ($98 million) in upgrading and expanding facilities at its production site in Kalundborg, Denmark.
The facilities targeted for investment manufacture a range of products for diabetes treatments and will...
Merck KGaA has announced an investment of EUR 150 million ($169 million) in its manufacturing site at Aubonne, Switzerland to expand manufacturing capacity for its biologic-based medicines.
The investment will cover a new building dedicated to...
AveXis, a Novartis company, has signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, Colorado, to expand its manufacturing capacity for its investigational gene therapy, Zolgensma (onasemnogene...
Novartis reports that it has a legal dispute with Amgen regarding the companies’ collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of termination of its migraine collaboration agreements with Novartis based...
Regeneron Pharmaceuticals, a Tarrytown, New York-based biopharmaceutical company, and Alnylam Pharmaceuticals, a Cambridge, Massachusetts-based company developing RNA interference (RNAi) therapeutics, have formed a collaboration, worth up to $1...
Novartis has completed the spin-off of Alcon, its eye-care device business, through a dividend-in-kind distribution to holders of Novartis shares and American depositary receipts (ADRs), with each holder receiving one Alcon share for every five...
Boehringer Ingelheim has completed the investment of EUR 105 million ($118 million) to expand associated production operations at its sites in Dortmund and Ingelheim, Germany for its Respimat inhaler.
Respimat is a propellant-free inhaler and the...
Xellia Pharmaceuticals, a specialty pharmaceutical company focused on anti-infective treatments and globally headquartered in Copehangen, Denmark, has entered into an agreement to divest its Raleigh, North Carolina manufacturing plant to Sagent...
Glenmark Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, has appointed Alessandro Riva, MD, as Chief Executive Officer of its new innovation company. Dr. Riva is currently Executive Vice President, Oncology Therapeutics and...
